Abingdon Health plc (LSE:ABDX) has appointed Cavendish Capital Markets Limited as its sole corporate broker and nominated adviser with immediate effect. The appointment brings the company’s advisory and broking arrangements under a single City firm, a move that could simplify capital markets access and strengthen investor engagement as Abingdon Health continues to expand its presence in international diagnostics and medical device markets.
From an investment perspective, the Group’s outlook remains shaped by a mixed financial profile. While revenue growth has been strong, this has been offset by ongoing profitability pressures and negative cash flow. Technical indicators point to a broadly neutral share price trend, with limited momentum in either direction. Valuation metrics also remain challenged, reflecting a negative P/E ratio and the absence of dividend yield support, resulting in a balanced but cautious overall assessment.
More about Abingdon Health PLC
Abingdon Health plc is a UK-based med-tech contract services provider specialising in the development, manufacture and regulatory support of rapid diagnostic tests and wider in vitro diagnostics for global customers. Through its CDMO operations, the Group delivers lateral flow assay development, technology transfer and manufacturing across infectious disease, clinical and companion diagnostics, animal health and environmental testing. Its regulatory and quality-focused subsidiaries offer consultancy, analytical testing and performance evaluation services from facilities in York and Doncaster in the UK, and Madison, Wisconsin in the United States.
Leave a Reply